Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04323956 | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma | active not recruiting | Phase 1 | 50 | Mayo ClinicOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05633615 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 396 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05784415 | Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell(CS22-03) | completed | — | 30 | AIDS Malignancy ConsortiumNETWORK | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07114939 | FTT PET/CT in Pancreatic Neuroendocrine Tumors | recruiting | Phase 1 | 12 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04285268 | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 2 | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04669171 | A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma(SIDNEY) | recruiting | Phase 1 / Phase 2 | 80 | EnteromeINDUSTRY | 4 | Jan 30, 2026 | clinicaltrials |
| NCT06068881 | A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation(Mandolin) | withdrawn | Phase 2 | 0 | Epizyme, Inc.INDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT06357676 | Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial | recruiting | Phase 1 / Phase 2 | 27 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06829771 | Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04745559 | Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy | active not recruiting | Phase 2 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04965493 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)(BRUIN CLL-322) | active not recruiting | Phase 3 | 600 | Loxo Oncology, Inc.INDUSTRY | 23 | Jan 29, 2026 | clinicaltrials |
| NCT05583149 | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | active not recruiting | Phase 2 | 28 | Patrick C. Johnson, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04116437 | Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment | completed | Phase 2 | 96 | BeiGeneINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06834373 | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | recruiting | Phase 2 | 41 | Mayo ClinicOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07368270 | Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 30 | Jiangsu Topcel-KH Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07371923 | Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 50 | Beijing Tongren HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07372365 | Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. | recruiting | Phase 2 | 23 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03740529 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | completed | Phase 1 / Phase 2 | 803 | Loxo Oncology, Inc.INDUSTRY | 10 | Jan 27, 2026 | clinicaltrials |
| NCT03842696 | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | active not recruiting | Phase 1 / Phase 2 | 43 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07355283 | IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma | not yet recruiting | Phase 3 | 198 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05665530 | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | completed | Phase 1 | 86 | Prelude TherapeuticsINDUSTRY | 10 | Jan 26, 2026 | clinicaltrials |
| NCT06693830 | ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL | recruiting | N/A | 40 | Hua-Jay J Cherng, MDOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06846463 | Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ | recruiting | Phase 2 | 21 | Virginia Commonwealth UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07360288 | Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma(TC011_FL_201) | not yet recruiting | Phase 2 | 40 | TICAROS Co., Ltd.INDUSTRY | 0 | Jan 22, 2026 | clinicaltrials |
| NCT04855695 | Avo In R/R And Previously Untreated MCL | recruiting | Phase 1 / Phase 2 | 72 | Austin I KimOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06333262 | Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 60 | Inhye AhnOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06575686 | Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | suspended | Phase 2 | 33 | City of Hope Medical CenterOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07077512 | Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma | recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07355699 | Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma | recruiting | Phase 4 | 88 | Beijing Tongren HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT01483664 | Communication Skills Intervention to Promote Transition Into Survivorship | active not recruiting | — | 314 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT04223765 | Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. | recruiting | Phase 1 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05222555 | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients(MINDway) | active not recruiting | Phase 1 / Phase 2 | 53 | Incyte CorporationINDUSTRY | 9 | Jan 16, 2026 | clinicaltrials |
| NCT01599559 | Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma | active not recruiting | N/A | 540 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 14 | Jan 15, 2026 | clinicaltrials |
| NCT01808599 | Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma | active not recruiting | Phase 2 | 112 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 3 | Jan 15, 2026 | clinicaltrials |
| NCT04855253 | Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL | suspended | Phase 1 / Phase 2 | 30 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05716087 | A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 2 | 62 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT02896582 | Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance(LyMa101) | completed | Phase 2 | 86 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03210662 | Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07335120 | A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma(ALMANAC) | recruiting | — | 800 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05211336 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System | active not recruiting | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05464329 | Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | active not recruiting | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04572763 | Copanlisib Plus Venetoclax in R/R DLBCL | active not recruiting | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04843904 | Safe Accelerated Venetoclax Escalation in CLL(SAVE) | active not recruiting | Phase 1 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05417165 | Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 80 | Seema BhatOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03674411 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | active not recruiting | Phase 2 | 22 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06031194 | Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma | completed | — | 20 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07014917 | Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL(ESR-23-22182) | recruiting | Phase 2 | 62 | Zulfa OmerOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07108998 | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL | recruiting | Phase 2 | 22 | Zulfa OmerOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03961672 | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 15 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Feb 2, 2026source: clinicaltrials